Literature DB >> 35451341

Animal models for studying COVID-19, prevention, and therapy: Pathology and disease phenotypes.

Shambhunath Choudhary1, Isis Kanevsky1, Lindsay Tomlinson2.   

Abstract

Translational models have played an important role in the rapid development of safe and effective vaccines and therapeutic agents for the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Animal models recapitulating the clinical and underlying pathological manifestations of COVID-19 have been vital for identification and rational design of safe and effective vaccines and therapies. This manuscript provides an overview of commonly used COVID-19 animal models and the pathologic features of SARS-CoV-2 infection in these models in relation to their clinical presentation in humans. Also discussed are considerations for selecting appropriate animal models for infectious diseases such as COVID-19, the host determinants that can influence species-specific susceptibility to SARS-CoV-2, and the pathogenesis of COVID-19. Finally, the limitations of currently available COVID-19 animal models are highlighted.

Entities:  

Keywords:  ACE2; COVID-19; SARS-CoV-2; animal models; disease phenotype; host susceptibility; pathology; review

Mesh:

Year:  2022        PMID: 35451341      PMCID: PMC9208071          DOI: 10.1177/03009858221092015

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   3.157


  86 in total

1.  Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.

Authors:  Elisabetta Cameroni; John E Bowen; Laura E Rosen; Christian Saliba; Samantha K Zepeda; Katja Culap; Dora Pinto; Laura A VanBlargan; Anna De Marco; Julia di Iulio; Fabrizia Zatta; Hannah Kaiser; Julia Noack; Nisar Farhat; Nadine Czudnochowski; Colin Havenar-Daughton; Kaitlin R Sprouse; Josh R Dillen; Abigail E Powell; Alex Chen; Cyrus Maher; Li Yin; David Sun; Leah Soriaga; Jessica Bassi; Chiara Silacci-Fregni; Claes Gustafsson; Nicholas M Franko; Jenni Logue; Najeeha Talat Iqbal; Ignacio Mazzitelli; Jorge Geffner; Renata Grifantini; Helen Chu; Andrea Gori; Agostino Riva; Olivier Giannini; Alessandro Ceschi; Paolo Ferrari; Pietro E Cippà; Alessandra Franzetti-Pellanda; Christian Garzoni; Peter J Halfmann; Yoshihiro Kawaoka; Christy Hebner; Lisa A Purcell; Luca Piccoli; Matteo Samuele Pizzuto; Alexandra C Walls; Michael S Diamond; Amalio Telenti; Herbert W Virgin; Antonio Lanzavecchia; Gyorgy Snell; David Veesler; Davide Corti
Journal:  Nature       Date:  2021-12-23       Impact factor: 69.504

2.  TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.

Authors:  Adeline Heurich; Heike Hofmann-Winkler; Stefanie Gierer; Thomas Liepold; Olaf Jahn; Stefan Pöhlmann
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

3.  The Roborovski Dwarf Hamster Is A Highly Susceptible Model for a Rapid and Fatal Course of SARS-CoV-2 Infection.

Authors:  Jakob Trimpert; Daria Vladimirova; Kristina Dietert; Azza Abdelgawad; Dusan Kunec; Simon Dökel; Anne Voss; Achim D Gruber; Luca D Bertzbach; Nikolaus Osterrieder
Journal:  Cell Rep       Date:  2020-11-19       Impact factor: 9.423

4.  A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice.

Authors:  Sarah R Leist; Kenneth H Dinnon; Alexandra Schäfer; Longping V Tse; Kenichi Okuda; Yixuan J Hou; Ande West; Caitlin E Edwards; Wes Sanders; Ethan J Fritch; Kendra L Gully; Trevor Scobey; Ariane J Brown; Timothy P Sheahan; Nathaniel J Moorman; Richard C Boucher; Lisa E Gralinski; Stephanie A Montgomery; Ralph S Baric
Journal:  Cell       Date:  2020-09-23       Impact factor: 41.582

5.  SARS-CoV-2 infection in K18-ACE2 transgenic mice replicates human pulmonary disease in COVID-19.

Authors:  Victor M Arce; Jose A Costoya
Journal:  Cell Mol Immunol       Date:  2021-01-14       Impact factor: 11.530

Review 6.  The state of complement in COVID-19.

Authors:  Behdad Afzali; Marina Noris; Bart N Lambrecht; Claudia Kemper
Journal:  Nat Rev Immunol       Date:  2021-12-15       Impact factor: 108.555

7.  Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models.

Authors:  Shambhunath Choudhary; Isis Kanevsky; Soner Yildiz; Rani S Sellers; Kena A Swanson; Tania Franks; Raveen Rathnasinghe; Raquel Munoz-Moreno; Sonia Jangra; Olga Gonzalez; Philip Meade; Timothy Coskran; Jessie Qian; Thomas A Lanz; Jillian G Johnson; Cassandra A Tierney; Justin D Smith; Kristin Tompkins; Arthur Illenberger; Paula Corts; Tara Ciolino; Philip R Dormitzer; Edward J Dick; Vinay Shivanna; Shannan Hall-Ursone; Journey Cole; Deepak Kaushal; Jane A Fontenot; Carles Martinez-Romero; Meagan McMahon; Florian Krammer; Michael Schotsaert; Adolfo García-Sastre
Journal:  Toxicol Pathol       Date:  2022-02-05       Impact factor: 1.930

Review 8.  Animal models for SARS-CoV-2 research: A comprehensive literature review.

Authors:  Kabita Pandey; Arpan Acharya; Mahesh Mohan; Caroline L Ng; St Patrick Reid; Siddappa N Byrareddy
Journal:  Transbound Emerg Dis       Date:  2020-12-20       Impact factor: 5.005

Review 9.  COVID-19 and the Endocrine System: A Comprehensive Review on the Theme.

Authors:  Giuseppe Lisco; Anna De Tullio; Assunta Stragapede; Antonio Giovanni Solimando; Federica Albanese; Martina Capobianco; Vito Angelo Giagulli; Edoardo Guastamacchia; Giovanni De Pergola; Angelo Vacca; Vito Racanelli; Vincenzo Triggiani
Journal:  J Clin Med       Date:  2021-06-29       Impact factor: 4.241

Review 10.  Clinical manifestations of COVID-19 in the general population: systematic review.

Authors:  Rodrigo da Rosa Mesquita; Luiz Carlos Francelino Silva Junior; Fernanda Mayara Santos Santana; Tatiana Farias de Oliveira; Rafaela Campos Alcântara; Gabriel Monteiro Arnozo; Etvaldo Rodrigues da Silva Filho; Aisla Graciele Galdino Dos Santos; Euclides José Oliveira da Cunha; Saulo Henrique Salgueiro de Aquino; Carlos Dornels Freire de Souza
Journal:  Wien Klin Wochenschr       Date:  2020-11-26       Impact factor: 2.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.